{"title":"卡铂治疗膀胱转移性移行细胞癌的II期研究(医学研究委员会泌尿肿瘤工作组，晚期膀胱癌亚组的报告)。","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In view of the activity of Cisplatin in bladder cancer a multicentre study of its less toxic analogue Carboplatin was carried out in 48 patients with metastatic transitional cell carcinoma, of whom 30 had received no previous cytotoxic chemotherapy. No complete remissions and only 3 partial responses were observed, suggesting that Carboplatin has only minimal activity in this disease.</p>","PeriodicalId":11941,"journal":{"name":"European journal of cancer & clinical oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In view of the activity of Cisplatin in bladder cancer a multicentre study of its less toxic analogue Carboplatin was carried out in 48 patients with metastatic transitional cell carcinoma, of whom 30 had received no previous cytotoxic chemotherapy. No complete remissions and only 3 partial responses were observed, suggesting that Carboplatin has only minimal activity in this disease.</p>\",\"PeriodicalId\":11941,\"journal\":{\"name\":\"European journal of cancer & clinical oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of cancer & clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of cancer & clinical oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer).
In view of the activity of Cisplatin in bladder cancer a multicentre study of its less toxic analogue Carboplatin was carried out in 48 patients with metastatic transitional cell carcinoma, of whom 30 had received no previous cytotoxic chemotherapy. No complete remissions and only 3 partial responses were observed, suggesting that Carboplatin has only minimal activity in this disease.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
